Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Analyst
UK
+3 year(s) experience
Since joining Datamonitor Healthcare’s CNS and Rare Diseases team in 2017, Stephanie has produced content on epilepsy, bipolar disorder and schizophrenia. She will further expand her coverage to include pulmonary hypertension, migraine and multiple sclerosis.
Prior to Informa, Stephanie gained experience as an editorial assistant in scientific publishing. She graduated from Imperial College London with a Biomedical Science degree.
As an analyst, Stephanie’s greatest achievement has been contextualizing key events through her understanding of market dynamics and integrating this knowledge into forecasts for a variety of diseases.
Datamonitor Healthcare
With the FDA’s landmark approval of Epidiolex, a cannabidiol used to treat rare, severe pediatric epilepsies, the only obstacle to the legal sale of the drug is DEA reclassification of cannabidiol (CBD). With reclassification likely in the next 90 days, what does it mean for the epilepsy market, as well as the wider market for CBD?
Topic Drug approval
